Koshinski Asset Management, Inc. Intellia Therapeutics, Inc. Transaction History

Koshinski Asset Management, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 18, 2022	BUY	$53.92 - $71.7 $39,631 - $52,699	735 New	735 $2.56 Million
Q2 2022 Jul 12, 2022	SELL	$38.49 - $76.21 $28,290 - $56,014	-735 Closed	0 $0
Q1 2022 Apr 20, 2022	SELL	$58.27 - $118.99 $32,339 - $66,039	-555 Reduced 43.02%	735 $53.4 Million
Q4 2021 Jan 14, 2022	SELL	$100.76 - $138.36 $12,091 - $16,603	-120 Reduced 8.51%	1,290 $153 Million
Q3 2021 Oct 12, 2021	BUY	$132.37 - $176.78 $186,641 - $249,259	1,410 New	1,410 $189,000

313

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $929M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Koshinski Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Koshinski Asset Management, Inc. with notifications on news.